IP Library Patent Application 16895443
Patent Application
App. No. 16/895,443

LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/895,443
Abstract

The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.

Claims (11)

1 . A lyophilized composition prepared by lyophilizing an aqueous solution comprising from 40 mM to 50 mM arginine, from 1% to 3% sucrose (w/v), from 2% to 8% mannitol (w/v) and 5 to 50 mg/mL of a two-chain polypeptide comprising a first chain comprising the amino acid sequence of SEQ ID NO. 4, a second chain comprising the amino acid sequence of SEQ ID NO. 5, and a disulfide bond between a first Cysteine residue at position 98 (Cys98) of SEQ ID NO. 4 and a second Cysteine residue at position 108 (Cys108) of SEQ ID NO. 5, wherein the aqueous solution has a pH from 7.7 to 7.9.

2 . The lyophilized formulation of claim 1 , wherein the aqueous solution comprises from 40 mM to 50 mM arginine, from 1.5% to 2.5% sucrose (w/v), from 4.5% to 5.5% mannitol (w/v) and at least 10 mg/mL of the polypeptide.

3 . The lyophilized formulation of claim 2 , wherein the aqueous solution comprises at least 18 mg/mL of the polypeptide.

4 . The lyophilized formulation of claim 1 , wherein the polypeptide comprises at least an intra-chain disulfide bond for each of the first and second chains.

5 . The lyophilized formulation of claim 1 , wherein the aqueous solution comprises about 45 mM arginine, about 2% sucrose (w/v), about 5% mannitol (w/v) and about 10 mg/mL of the two-chain polypeptide, wherein the aqueous solution has a pH of about 7.8.

6 . The lyophilized formulation of claim 1 , wherein the aqueous solution comprises about 45 mM arginine, about 2% sucrose (w/v), about 5% mannitol (w/v) and about 20 mg/mL of the two-chain polypeptide, wherein the aqueous solution has a pH of about 7.8.

7 . The lyophilized formulation of claim 1 , which comprises L-arginine HCl:sucrose:mannitol in a weight ratio of the range of (0.5-1.4):(1-3):(2-8).

8 . The lyophilized formulation of claim 1 , which comprises L-arginine HCl:sucrose:mannitol in a weight ratio of the range of (0.9-1):(1.5-2.5):(4.5-5.5).

9 . The lyophilized formulation of claim 1 , which comprises L-arginine HCl:sucrose:mannitol in a weight ratio of about 0.95:2:5.

10 . An aqueous solution comprising from 40 mM to 50 mM arginine, from 1% to 3% sucrose (w/v), from 2% to 8% mannitol (w/v) and 5 to 50 mg/mL of a two-chain polypeptide comprising a first chain comprising the amino acid sequence of SEQ ID NO. 4, a second chain comprising the amino acid sequence of SEQ ID NO. 5, and a disulfide bond between a first Cysteine residue at position 98 (Cys98) of SEQ ID NO. 4 and a second Cysteine residue at position 108 (Cys108) of SEQ ID NO. 5, wherein the aqueous solution has a pH from 7.7 to 7.9.

11 . An aqueous solution prepared by dissolving the lyophilized formulation of claim 1 in water.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2022
From: ALEXION PHARMACEUTICALS, INC.
To: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
Reel/Frame 060799/0729 →
CHANGE OF NAME Recorded Jan 7, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054920/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054921/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054922/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2020
From: WANG, JUAN; SACHA, GREGORY A.; NGUYEN, PHUONG M.
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 052880/0890 →